# Ruihe Capital

> Ruihe Capital is a VC fund backing Pharmaceutical, Medical and Biotechnology. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 20
- Last investment: Jun 2024
- Lead investor: 5%
- Last updated: Aug 2026

Ruihe Capital is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 7 | 35% |
| Medical | 5 | 25% |
| Biotechnology | 4 | 20% |
| Biopharma | 3 | 15% |
| Health Care | 3 | 15% |

32 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 35% |
| Series B | 3 | 15% |
| Venture - Series Unknown | 3 | 15% |
| Seed | 2 | 10% |
| Series D | 2 | 10% |

8 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Leming Pharmaceuticals | Le Ming Pharmaceuticals is a pharmaceutical enterprise focusing on R&D, production and sales of innovative pharmaceutical preparation. | $13.8M | Venture - Series Unknown | Jun 07, 2024 |  |
| Xinyue | Yuejing Network Technology Co., Ltd. is a digital video assistant platform that cuts in the communication and review links in the video production stream, helping to achieve multi-platform preview of video demos in video production and convenient review comments and video storage. sort out. With the subsequent connection of external hardware, theuser can realize the real-time synchronization of the video data captured in the camera to the new cloud server, and later can synchronize production and storage sharing through the new reading. | $1.4M | Series A | May 11, 2024 |  |
| AffectOR MedTech | AffectOR MedTech is a medical technology company that specializes in cardiac electrophysiology and energy surgical treatment. |  | Seed | Nov 06, 2023 |  |
| Nalinway Nano Technology | Nalinway Nano Technology is a research center. They provide products that include the products world, nano slurry, modified masterbatch, and ceramic coating. They offer services for film, sheet, film, injection molding, spinning, and polymerization. | $13.7M | Series D | Nov 03, 2023 |  |
| Yihe Pharmaceutical | Yihe Pharmaceutical is a technology innovation company that focuses on inhalation preparations, inhalation devices, and supporting equipment. | $6.8M | Series A | Oct 16, 2023 |  |
| LEADRIVE | LEADRIVE is a technology company that focuses on the research and development, production, and sales of new energy vehicle drive solutions and high-performance domestic power semiconductor modules. The company is developing a variety of high-performance motor controllers and self-developed power modules for new energy vehicles, which have wondomestic and foreign first-line passenger cars more than 10 models of OEMs and Tier-1 suppliers have been mass-produced and designated, and OEM certification progress for silicon carbide modules and electronic controls is in progress.LEADRIVE is also constantly investing and innovating in the field of new energy equipment such as wind energy, solar energy, and energy storage, and has taken the lead in realizing the localization of power semiconductor modules. LEADRIVE and Japan Rohm Semiconductor have established a joint laboratory to complete the iterative development of a variety of silicon carbide modules and realized simulation, testing, and efficiency from the device, and electronic control, to vehicle-level, promote. | $82.3M | Series D | Oct 09, 2023 |  |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $40M | Post-IPO Equity | Sep 29, 2023 |  |
| Kangpu Biopharmaceuticals, Ltd. | Kangpu is focused on developing small molecule drugs targeting immuno-modulating sites to develop treatments for cancer, autoimmune diseases and inflammation. The company has developed proprietary technologies to generate and degrade ubiquitin-protein. It also has a drug discovery combination platform called X-Synergy®. | $13.7M | Series B | Aug 30, 2023 |  |
| Furbulous | Furbulous is an online retailer that specializes in pet supplies and accessories for dogs and cats. They provide self-cleaning and packed cat litter boxes. They sell glaring litter, furbulous boxes, deodorant bars, trash bag boxes, fruity vibes nail clippers, pet bath brushes, cat litter boxes, and pet brushes. |  | Angel | Aug 23, 2023 |  |
| Leming Pharmaceuticals | Le Ming Pharmaceuticals is a pharmaceutical enterprise focusing on R&D, production and sales of innovative pharmaceutical preparation. |  | Series A | Apr 14, 2023 |  |

10 of 20 investments shown.

## Co-investors
- [Lenovo Capital and Incubator Group (LCIG)](https://shizune.co/investors/profile/lenovo-capital-and-incubator-group-lcig) — VC Fund, 2 deals together
- Ruihe Venture Capital — VC Fund, 2 deals together
- [Anker Innovations](https://shizune.co/investors/profile/anker-innovations) — VC Fund, 1 deal together
- Beedie School of Business at Simon Fraser University — VC Fund, 1 deal together
- [Buer Capital](https://shizune.co/investors/profile/buer-capital) — VC Fund, 1 deal together
- C Capital — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ruihe Capital invest in?

Ruihe Capital invests primarily in Pharmaceutical, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ruihe Capital last invest?

The most recent investment recorded for Ruihe Capital closed in Jun 2024. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co